We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Ask ADVFN Intelligence (AI)
Oxford BioTherapeutics Appoints Bryan G. Morton as Chairman PR Newswire OXFORD, England, June 26, 2013 OXFORD, England, June 26, 2013 /PRNewswire/ -- Oxford BioTherapeutics (OBT), a global...
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and...
• Blackstone Group (NYSE:BX) posted a Q3 loss of $0.31 per share, lower than the Zacks Consensus Estimate of $0.05 per share • KeyCorp (NYSE:KEY...
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has completed its acquisition of Cephalon, Inc. (NASDAQ: CEPH). The combined company will have a...
The European Commission's Antitrust unit cleared Friday the acquisition of US-based pharmaceutical company Cephalon Inc. (CEPH) by the generic pharmaceutical company Teva Pharmaceuticals...
Since inception in 1988, the S&P 500 has outperformed the Zacks #5 Rank List - Stocks to Sell Now by 80% annually (+2% versus +10%). While the rest of Wall Street continued to tout stocks during...
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Cephalon Inc. (NASDAQ: CEPH) announced today that they received approval from the European Commission to proceed with...
S&P Indices Announces Change to U.S. Index PR Newswire NEW YORK, Oct. 11, 2011 NEW YORK, Oct. 11, 2011 /PRNewswire/ -- TE Connectivity Ltd. (NYSE: TEL) will replace Cephalon Inc. (NASD: CEPH) in...
Teva Pharmaceutical Industries Ltd. (TEVA) is a step closer to acquiring Cephalon, Inc. (CEPH) with the US Federal Trade Commission (FTC) accepting the proposed consent order in connection with...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
